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Abstract 
 
Background Narrowband (TL-01) UVB phototherapy (UVB nb) is effective in treating 
inflammatory skin disease. The addition of UVA is traditionally advocated to reduce 
pruritus, but lacks evidence for this recommendation. 
 
Objectives The aim of this study was to assess the effect of UVB nb and UVA 
phototherapy in combination compared against UVB nb monotherapy on pruritus, 
disease activity, and quality of life. 
 
Methods In this double-blind randomised clinical trial 53 patients suffering from 
inflammatory skin diseases with pronounced itching (Visual Analogue Scale (VAS) for 
pruritus ≥ 5) were randomised in to two treatment groups. One group received UVB nb 
(311nm) phototherapy alone and another group received a combination of UVB nb and 
UVA (320-400nm) phototherapy. UV therapy was performed three times per week over 
16 weeks. Pruritus (VAS and 5-D itch score), disease activity and quality of life 
(Dermatology Life Quality Index, DLQI) were assessed at baseline and weeks 4, 8, 12, 
and 16. 
 
Results In both treatment groups there was a reduction in pruritus scores, disease 
activity and DLQI. No difference in pruritus score, disease activity, and quality of life 
could be detected between the group receiving UVB nb alone and those receiving UVB 
nb combined with UVA. 
 
Conclusions Phototherapy with UVB nb and UVB nb combined with UVA are equally 
effective in treating inflammatory skin disease and indifferent in reducing disease-
associated pruritus. Given this non-inferiority for UVB nb monotherapy, the 
recommendation of adding UVA to UVB nb phototherapy for pruritic inflammatory skin 
disease should be abandoned.  
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Introduction 
 
Vexing pruritus is a disturbing and highly prevalent symptom associated with many 
inflammatory skin diseases. It is a major diagnostic criterion for atopic dermatitis[1] and 
affects 84% of patients suffering from psoriasis, .[2] The impact of pruritis on health-
related quality of life (QoL) is comparable to patients suffering from chronic pain.[3, 4] 
Effective therapies are therefore critically needed, and phototherapy is generally 
acknowledged to provide an important contribution in reducing pruritus.[5] Distinct 
types of ultraviolet (UV) radiation are routinely used, long-wave UVA,[6] short-wave 
UVB nb,[7] or a combination of both (UVB nb and UVA).[8] As all these types are 
suitable for treating inflammatory skin diseases, the actual choice of radiation appears 
insignificant. However, different mechanisms by which the generation of pruritus can 
be inhibited have been discussed, and are generally linked to the penetration depth of 
UV into the affected skin. UVB is thought to mainly affect epidermal keratinocytes and 
Langerhans cells, while UVA can also affect dermal T lymphocytes, mast cells, 
fibroblasts and dendritic cells.[9] Both types of UV radiation are able to alleviate 
histamine-induced pruritus in healthy volunteers, but an additional induction of 
hyposensitivity to pruritic stimuli has been proposed for UVB.[10] In addition, an in vitro 
study showed that UVA and UVB radiation are both able to inhibit histamine release 
from mast cells, but only UVA can inhibit histamine release from basophils.[11] A 
further layer of complexity is added by the systemic effects of UV on immune function, 
which can be seen in half-body irradiation studies.[8] From these findings, it can be 
hypothesized that UVA and UVB radiation possess a distinct intrinsic potential to 
reduce pruritus, or could even have an additive effect when combined. Whether this is 
true in day-to-day clinical UV treatment of inflammatory skin diseases remains 
unknown however. 
 
In this study we investigated the benefit of combination UVB nb and UVA phototherapy 
versus UVB nb monophototherapy in relieving pruritus, reducing disease activity, and 
improving the QoL of patients affected by various pruritic inflammatory skin diseases. 
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Materials and methods 
 
 
Patients 
 
This randomised double-blind clinical trial (ClinicalTrials.gov identifier: NCT01254240) 
was performed in the outpatient clinic, Department of Dermatology, University Hospital 
Zurich, between 2010 and 2015. Eligible patients were all over the age of 18 years, 
suffered from inflammatory skin disease (e.g. atopic dermatitis, other eczema 
subtypes, psoriasis, prurigo simplex subacuta, and others (see table 1)), had pruritus 
VAS scores ≥ 5, and had an indication for phototherapy. Exclusion criteria included 
foreseeable interruption of the light therapy for more than 14 days. Patients were 
further excluded if they displayed heightened photosensitivity to UVA or UVB, withdrew 
their consent to participate, concomitantly participated in another study or had taken 
part in another clinical study within the last 30 days. 
The study was performed in accordance with the Declaration of Helsinki principles, 
and was approved by the Medical Ethics Committee of Zurich. All participants gave 
oral and written informed consent. 
 
 
Study design 
 
Patients included in the study were randomized in a 1:1 ratio in to two treatment arms 
(Fig. 1). One group received phototherapy with UVB nb (311nm) and another group 
received a combination of UVB nb and UVA (UVB nb/UVA; 320-400nm). Therapy was 
performed three times per week over a course of 16 weeks. At baseline, start of therapy 
and at 4, 8, 12, and 16 weeks, pruritus (VAS and 5-D itch score), disease activity (PASI, 
EASI, PSGA, DDV respectively), as well as QoL (DLQI) were assessed. Where 
indicated, last-observation-carried-forward (LOCF) analysis was used to impute 
missing data.[12] Randomization was performed with sealed envelopes. Patients and 
investigators were blinded concerning treatment assignment. 
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Dosages and administration 
 
Phototherapy was performed in the physical therapy unit of the Department of 
Dermatology in accordance with the standard light therapy protocol, as previously 
described.[13] Briefly, UVB nb treatment is started at a dosage of 0.1J/cm2. In the 
absence of side effects, such as UV-induced erythema, the dosage was increased in 
increments of 20% per session, to a maximum dosage of 2.0 J/cm2. Phototherapy was 
typically administered over a time course of 16 weeks, with 3 treatment sessions per 
week. For UVB nb/UVA treatment, UVA was additionally administered at a dosage of 
0.5 J/cm2 during standard UVB nb treatment, and was increased in increments of 20%, 
to a maximum dosage of 5.0 J/cm2. 
Phototherapy was performed with a UVB nb light cabin (Model UV7001, Waldmann 
[Waldmann Lichttechnik GmbH, Küttingen, Switzerland], output 310-315nm), and 
UVA/UVB nb light cabin (Model UV7002, Waldmann, UVA output 320-410nm, peak 
351nm; UVB output 310-315nm, peak 311nm). The radiation sources irradiated all 
body surface areas with equal intensity. 
 
 
Efficacy and safety measures 
 
The primary efficacy endpoint was pruritus score change after completion of 
phototherapy at 16 weeks, as assessed by VAS and 5-D itch score. Secondary 
endpoints were disease activity (PASI, EASI, PSGA, DDV respectively), and health-
related QoL (DLQI questionnaire). At each study visit, patients received a physical 
examination and were screened for adverse events. 
 
 
Statistical methods 
 
Statistical analysis was performed with Prism 5.0 for windows (GraphPad Software, La 
Jolla, USA). Normality distribution of the data was assessed with the D'Agostino-
Pearson omnibus test. P-values were calculated using the Student's t-test and the 
Mann-Whitney test, as indicated in the figure legends. Fisher`s exact test and Chi-
 6 
square test were used to compare the baseline characteristics of both treatment 
groups from contingency tables. Bars depict the mean.  
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Results 
 
A total of 53 patients were enrolled in the study (UVB nb, n=27; UVB nb/UVA, n=26). 
45 patients completed the trial and were analysed at week 16 (UVB nb, n= 24; UVB 
nb/UVA, n=21). Due to loss of follow-up after the first study visit, 3 patients in the UVB 
nb treatment group, and 5 patients in the UVB nb/UVA treatment group were excluded 
due to work-related, private or withheld reasons, but none because of adverse events. 
Baseline characteristics were similar across both treatment arms (Table 1), with the 
vast majority of patients in both groups suffering from different forms of eczema 
(53,8%), psoriasis (25,0%), prurigo simplex subacuta (7,7%), and pruritus sine materia 
(3,8%). At baseline 40,9% of patients reported a history of previous phototherapy. No 
severe adverse events occurred, three adverse events were recorded, namely two 
exacerbations during UVB nb/UVA treatment (one atopic eczema and one lichen 
planus). A third patient with atopic eczema developed suberythroderma and regressed 
after continuation of the phototherapy. No adverse events were seen in the UVB nb 
treatment group. The difference between both treatment groups was not significant (p 
< 0.112). 
In order to assess pruritus within our patient population, simultaneous monitoring via 
the visual analogue scale (VAS),[14] and the 5-D itch score [15] was chosen. 
Compared to the one-dimensional quantification of pruritus intensity, the latter score 
has the additional advantage of additionally quantifying the duration, degree, direction, 
disability, and distribution of this symptom. According to the study inclusion criteria, all 
patients displayed VAS pruritus values ≥ 5 (UVB nb, 7.2; UVB nb/UVA, 7.0), which 
corresponded well with high values for pruritus as assessed by the 5-D itch score (UVB 
nb, 20.9; UVB nb/UVA, 19.8). Before the start of treatment, no differences between 
both treatment groups could be detected for evaluation with either pruritus score (VAS, 
p = 0.7491; 5-D itch score, p = 0.8241) (Fig. 2a, b). After phototherapy, pruritus VAS 
scores declined (UVB nb, 2.0, p < 0.0001; UVB nb/UVA, 2.5, p = 0.0001) to similar 
levels of 27.96% (+/- SEM of 6.859%) for UVB nb alone and 35.21% (+/- SEM of 
10.60%) for combined UVB nb/UVA. Correspondingly, 5-D itch score values declined 
(UVB nb, 10.5, p < 0.0001; UVB nb/UVA, 13.3, p = 0.0038) to similar levels of 50.45% 
(+/- SEM of 6.033%) for UVB nb alone and 67.00% (+/- SEM of 6.877%) for combined 
UVB nb/UVA. No difference could be observed between either treatment modality 
(VAS, p = 0.4486; 5-D itch score, p = 0.1510), suggesting that UVB nb and combination 
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UVB nb/UVA therapy are equally effective in relieving disease-associated pruritus. In 
order to confirm the validity of both tools, VAS and 5-D itch score values were 
correlated. For both treatment regimens, a high positive correlation could be observed 
(UVB nb, r = 0.68, p = 0.0007; UVB nb/UVA, r = 0.71, p = 0.0182) (Fig. 2c), thereby 
confirming the validity with which both scores assess pruritus as a subjective symptom. 
In order to investigate whether the reduction in pruritus scores was accompanied by a 
comparable reduction in disease activity, clinical scores (PASI, EASI, PSGA, DDV) 
were analyzed for both treatment regimens. Before the start of treatment, no difference 
in disease activity could be detected between both treatment groups (p = 0.8651) (Fig. 
3; UVB nb, 12.9; UVB nb/UVA, 11.4). After phototherapy, disease activity scores were 
reduced (UVB nb, 2.2, p < 0.0001; UVB nb/UVA, 1.7, p = 0.0005) to similar levels of 
17.44% (+/- SEM of 3.771%) for UVB nb alone and 14.89% (+/- SEM of 5.645%) for 
combined UVB nb/UVA. No difference between both treatment modalities could be 
observed (p = 0.4323). This indicates that UVB nb and UVB nb/UVA are equally 
effective in reducing disease activity within our patient collective. 
 
In addition to clinical scores, questionnaires which assess the QoL are useful in order 
to obtain additional information on individual disease manifestation.[16] As 
inflammatory skin diseases can be accompanied by a strong impairment in QoL,[17] 
we investigated whether phototherapy led to an overall improvement within our study 
population. Notably, before the start of treatment, higher baseline DLQI values and a 
higher degree of impairment was observed within the UVB nb/UVA treatment group 
(DLQI 15.5), compared to the UVB nb treatment group (DLQI 11.2) (Fig. 4; p = 0.0449). 
After phototherapy, DLQI values were reduced (UVB nb, 5.8, p = 0.0024; UVB nb/UVA, 
6.5, p = 0.0023) to similar levels of 51.57% (+/- SEM of 10.43%) for UVB nb alone and 
42.23% (+/- SEM of 11.78%) for combined UVB nb/UVA, thus indicating a strong 
improvement in QoL for both treatment modalities (p = 0.7034). Due to the initially 
disparate baseline DLQI values in each group, the average reduction relative to their 
starting values was compared, but no difference could be determined (p = 0.5776). 
These findings suggest that UVB nb and UVB nb/UVA mediate an equally strong effect 
on the health-related QoL within our study population. 
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Discussion 
 
Our study confirms the results from previous reports, which highlight the efficacy of 
UVB nb and combination UVB nb/UVA phototherapy for the treatment of inflammatory 
skin disease.[7, 8] In both treatment groups a reduction in pruritus, and disease activity 
could be observed, further accompanied by an improvement in QoL. However, no 
difference in efficacy – when considering each of the above 3 parameters - could be 
demonstrated between phototherapy with UVB nb or combination UVB nb/UVA. 
While the exact modes of action for different types of UV phototherapy are still under 
investigation, an additive effect for UVA on UVB has been proposed.[18] In our clinical 
trial comparing these two modalities, the lack of superiority of combined UVB nb/UVA 
therapy over UVB nb alone argues against an additional benefit of UVA, compared to 
exclusive UVB nb therapy. However, given the size of our study groups, we cannot 
exclude a discrete additional effect of UVA within combination phototherapy. This 
possibility could be further investigated by comparing UVB nb/UVA with exclusive UVB 
nb treatment in future studies. 
 
Several acute and chronic side effects have been associated with increased exposure 
to each type of UV radiation. Reactions include inflammation, local or systemic 
immunosuppression, photoageing, and carcinogenesis.[19] UVA in particular can 
induce DNA damage in skin cells via activation of endogenous photosensitisers, 
resulting in local oxidative stress.[20] In view of these cumulative side effects, the 
lacking evidence for clear superiority of combination UVB nb/UVA phototherapy, and 
the increased amount of treatment time as well as cost of treatment, the previously 
recommended addition of UVA should be abandoned. We thus recommend that the 
indication for combination UVB nb/UVA phototherapy should be critically scrutinised 
on an individual basis, in order to prevent exposing patients to side effects in the 
absence of additional therapeutic benefit. 
 
In conclusion, our study underlines, as previously reported by others, the value of 
phototherapy in the treatment of pruritus associated with inflammatory skin disease. 
We have demonstrated that disease activity is effectively reduced by both UVB nb and 
combined UVB nb/UVA phototherapy. In addition, patients treated by phototherapy 
benefit from a strong improvement in health-related quality of life. However, 
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combination phototherapy does not provide a significant advantage as far as reduction 
of pruritus, disease activity and quality of life are concerned. In view of the indifferent 
efficacy of both treatment modalities, and the potential long term side effects of added 
UVA therapy, we recommend that the indications for combined UVB nb/UVA 
phototherapy should be handled restrictively. 
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Table 1 Baseline characteristics of the patients       
 Treatment group   
 UVB nb UVB nb/UVA Total  
Characteristic* n=27 n=26 n=53 P-Value 
Age - years, median (range) 58.0 (23-83) 46.5 (19-75) 49.0 (19-83) 0.0995 
Sex - no. (%)    0.4064 
       Male 18 (66.7) 14 (53.8) 32 (60.4)  
       Female 9 (33.3) 12 (46.2) 21 (39.6)  
Height - m, median (range) 1.76 (1.58-1.88) 1.74 (1.55-1.92) 1.74 (1.55-1.92) 0.8938 
Weight - kg, median (range) 80.0 (45.5-118.5) 72.6 (47.8-110.0) 76.8 (45.5-118.5) 0.2868 
BMI** - kg m-2, median (range) 26.8 (18.0-39.1) 24.2 (18.7-36.7) 25.9 (18.0-39.1) 0.0628 
Fitzpatrick skin type - no. (%)    0.5243 
       Type I - - -  
       Type II 14 (58.3) 13 (56.5) 27 (57.4)  
       Type III 10 (41.7) 8 (34.8) 18 (38.3)  
       Type IV - 1 (4.3) 1 (2.1)  
       Type V - 1 (4.3) 1 (2.1)  
       Type VI - - -  
History of phototherapy - no. (%)    0.5467 
       Positive 11 (45.8) 7 (35.0) 18 (40.9)  
       Negative 13 (54.2) 13 (65.0) 26 (59.1)  
Diagnosis - no. (%)    0.1317 
       Eczema 11 (40.7) 16 (61.5) 27 (50.9)  
              Atopic eczema 10 (37.0) 14 (53.8) 24 (45.3)  
              Nummular eczema 1 (3.7) 1 (3.8) 2 (3.8)  
              Unclassifiable eczema 0 1 (3.8) 1 (1.9)  
       Psoriasis 10 (37.0) 4 (15.4) 14 (26.4)  
       Prurigo simplex subacuta 1 (3.7) 4 (15.4) 5 (9.4)  
       Pruritus sine materia 1 (3.7) 1 (3.8) 2 (3.8)  
       Others*** 4 (14.8) 1 (3.8) 5 (9.4)   
*Discrepancy from total number of included patients may reflect incomplete data acquisition; **BMI, body mass 
index; ***T cell lymphoma, Lichen planus, Folliculitis, Pityriasis lichenoides chronica, Prurigo nodularis. 
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Figure legend 
 
Fig. 1 Study design. Patients included in the study were randomized 1:1 and either received 
phototherapy 3 times per weeks with UVB nb, or UVB nb/UVA. At baseline at the start of therapy, after 
4, 8, 12, and 16 weeks patients were examined, and pruritus (VAS and 5-D itch score), disease activity 
(PASI, EASI, PSGA, DDV), and quality of life (DLQI) were assessed. 
 
Fig. 2 Pruritus is effectively reduced after phototherapy with UVB nb or combination UVB nb/UVA. (a) 
Scatter plots depict pruritus VAS values for UVB nb (black circles) or combination UVB nb/UVA 
phototherapy (open circles), before the start of treatment (V1), and as the last-observation-carried-
forward (LOCF). (b) As in (a), but for pruritus, as assessed by the 5-D itch score. (c) Scatter plots depict 
correlation of pruritus VAS and 5-D itch score values. *P < 0.05, **P < 0.005, ***P < 0.001 (Mann-
Whitney test (a, b), Spearman nonparametric testing (c)). 
 
Fig. 3 Disease activity is effectively reduced after phototherapy with UVB nb or combination UVB 
nb/UVA. Scatter plots depict the disease activity score for UVB nb (black circles) or combination UVB 
nb/UVA phototherapy (open circles), before the start of treatment (V1), and as the last-observation-
carried-forward (LOCF). ***P < 0.001 (Mann-Whitney test). 
 
Fig. 4 Quality of life is effectively improved after phototherapy using UVB nb or combination UVB 
nb/UVA. Scatter plots depict DLQI values for UVB nb (black circles) or combination UVB nb/UVA 
phototherapy (open circles), before the start of treatment (V1), and as the last-observation-carried-
forward (LOCF). *P < 0.05, **P < 0.005 (Student's t-test). 
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